Hyperinflation Nation – The Fall of the USD
June 29, 2009
|
Random Posts
Posted in Videos 
No Comments »
Conference Call – Access Pharmaceuticals Inc.
June 24, 2009
Access Pharmaceuticals Inc.
(OTC:ACCP)
At approximately 5:00pm EST, 6/23/09, StocksHaven Investments began the call conference scheduled with Director & CEO of Access Pharmaceuticals Inc., Mr. Jeffrey B. Davis, whom was also joined by Director & Consultant, Mr. David Luci. The basis of the interview was to provide an executive summary, along with their respective business strategy. Mr. Davis shed light on acquisitions, partnerships, current and future plans, and also discussed preparations to re-rejoin a major exchange. The interview was concluded as of 6:05pm EST, 6/23/09.
The exclusive StocksHaven Investments interview:
If you are experiencing technical difficulties, please visit this link. You will be taken to the original source of the mp3 file where your automatic preset media player should make the file play.
Update: For best results please use Mozilla Firefox version 3.0.10 web browser
Random Posts
Posted in Conference Call 1 Comment »
BioElectronics Corp. (OTC:BIEL) – A Doubled Edged Sword
June 19, 2009
BioElectronics Corporation
(OTC:BIEL)
BioElectronics is a company which is plagued by a poor financial balance sheet, unaudited filings and barely sustainable ongoing operations with its current expenses constantly exceeding revenues, however is it worth investing in? Here is a top-down unbiased analysis which tells all, investigating deeper into the lion’s den.
Random Posts
Posted in Stock Picks 1 Comment »
Nephros (OTC:NEPH): Three FDA Decisions, One Company
June 17, 2009
Nephros, Inc.
(OTC: NEPH)
A reader of StocksHaven Investments by the name of Michael Sklar has contributed the following article regarding Nephros, Inc. The article outlines one of the most undervalued BioPharma companies around, at only $1.08 PPS with three pending FDA decisions. If you are an avid investor of pre-PDUFA companies, StocksHaven Investments highly suggests you conduct some due diligence on this company, as its potential value greatly outweighs the risks involved.
READ FULL ARTICLE »
Random Posts
Posted in Stock Picks 3 Comments »
Third Time’s A Charm For Nuvo Research (TSE:NRI), (PINK:NRIFF)
June 16, 2009
Nuvo Research Inc.
Nuvo Research Inc. has been red hot this past month and is expected to continue. StocksHaven Investments has identified Nuvo Research as its top candidate for undervalued biotech pre-PDUFA. With a current PPS below $1.00 CAD, and their product Pennsaid, a new and innovative treatment for osteoarthritis having expected net sales of $200-400 million in the U.S., Nuvo Research (TSE:NRI), (PINK:NRIFF) could see extensive gains leading prior to their expected FDA decision on Aug/5/09 as investors gain confidence in the company once again.
READ FULL ARTICLE »
Random Posts
Posted in Stock Picks 7 Comments »
Hot FDA Trade: BioDelivery Sciences International
June 13, 2009
BioDelivery Sciences International
(NASDAQ:BDSI)
Continuing with the trend of pre-FDA decision BioPharma companies, StocksHaven Investments takes a closer look at BDSI which hopes its product Onsolis will strive past approval and make its way onto shelves world-wide.
Random Posts
Posted in Stock Picks 7 Comments »
Hemispherx (AMEX:HEB) Seeks Rebound: Phase 6 Flu Pandemic
June 11, 2009
With the World Health Organization (WHO) officially declaring the flu a pandemic of phase 6, one company looking to make waves is Hemispherx BioPharma (AMEX:HEB).
Hemispherx has recently been in limbo awaiting FDA decision on the long-awaited treatment for Chronic Fatigue Syndrome (CFS), Ampligen.
Ampligen, also known as poly I:poly C12U, is an experimental immunomodulatory double stranded RNA drug developed by HEMISPHERx Biopharma of Philadelphia, Pennsylvania. Ampligen was first synthesized in the 1970s and has been proposed and tested as a treatment for many illnesses, but primarily chronic fatigue syndrome (ME/CFS) and acquired immunodeficiency syndrome (AIDS).
Summary of articles
Identifying Fact vs. Fiction on Hemispherx’s Ampligen
Hemispherx Ampligen Combats H5N1
Post Approval Hemispherx Ampligen PPS Evaluation
Conference Call – Hemispherx Responds to TheStreet.com
Hemispherx Fights Back Against Feuerstein
Conference Call – Hemispherx BioPharma, Inc.
Taking on influenza
Hemispherx has a broad-based technology platform for confronting the potential of an influenza pandemic, which consists of both preventative (vaccine) components as well as experimental therapeutic interventions. Clinical results from trials conducted in Australia are being evaluated and major vaccine initiatives in Japan are being accelerated in collaboration with the Japanese National Institutes of Health and the Japanese Ministry of Health. According to the Japanese National Institute of Infectious Diseases Scientists Identify Hemispherx Biopharma’s Drug Technology as the “Most Promising Mucosal Adjuvant for Influenza.”
StocksHaven Investments believes the phase 6 declaration presents a strong buy signal for Hemispherx BioPharma (AMEX:HEB), within both the short-term and long-term.
—–
Disclosure: Long-Term Position
—–
By reading StocksHaven Investments you agree to the disclaimer, and thereby will not hold Michael Vlaicu accountable for any transactions or decisions you make. It is up to you to do your own due diligence.
Random Posts
Posted in Stock Picks 4 Comments »
Gaining Momentum – Access Pharmaceuticals (OTC:ACCP)
June 10, 2009
Access Pharmaceuticals (OTC:ACCP), a once struggling and troubled company, Access has put these issues behind them and is emerging as one of the top undervalued players in the BioPharma industry. Not only does this company have products which target a large and extensive market, but they are also implementing solid fundamentals within business management principals.
Among other things is a favourable stock price, management and board are significant shareholders (4.53M), and a low number of outstanding shares (21.9M), of these 11.3M common, 10.6M preferred which will be converted to common. Thus the market cap on Yahoo / Google finance is greatly understated by approximately 50%, as at $2 PPS it should be roughly $44M. This certainly shows belief in the future outlook of the potential revenue from their products rather than dilution. StocksHaven Investments believes they are poised for a turnaround and will soon see fit on the Nasdaq and AMEX exchanges. Moreover, Griffin Securities has given Access a 12-month target PPS of $7.50 (.pdf), and it has received the maximum possible Buy Rating from Reuters.
*All numbers above have been verified with Access Pharmaceuticals upper management
READ FULL ARTICLE »
Random Posts
Posted in Stock Picks 6 Comments »
Identifying Fact vs. Fiction on Hermispherx’s Ampligen
June 7, 2009
Much to the delight of Hemispherx BioPharma individual and institutional investors, a reader and follower of StocksHaven Investments has identified several key points which have been raised recently, decyphering the fact from fiction.
The following article has been submitted by an investor named, Nick DeCesare
————-
After reviewing my own research, it is time to post some serious points, some of which have already been raised by other investors and some have not.
First of all, Mr. Feuerstein has questioned the safety record of Ampligen. The FACT is, when it began as a compassionate emergency treatment (granted by the FDA several years back), that very agency required HEB to submit monthly safety reports. As of approximately one year ago, the FDA contacted HEB via telephone call, to let them know these reports were no longer needed.
Random Posts
Posted in General Advice, Stock Picks 30 Comments »
Hemispherx Ampligen Combats H5N1
June 3, 2009
With the majority of the focus being placed on on the current pending FDA approval regarding (AMEX:HEB) Hemispherx’s Ampligen, StocksHaven Investments would like to shift the attention on the drug’s ability to help treat the potential outbreak of H5N1 (subtype of the Influenza A virus).
Overview of H5N1
Also called “Influenza A (H5N1) virus” – is an influenza A virus subtype that occurs mainly in birds, is highly contagious among birds, and can be deadly to them. H5N1 virus does not usually infect people, however recently the infections with these viruses have began to occur in humans.
Random Posts
Posted in Internet News, Market News 14 Comments »
![[Valid RSS]](http://www.universalwrecking.com/images/uploads/validrss.png "Validate my RSS feed")
StocksHaven Talk